Well we've officially crossed the "17.5 month" timeframe alluded to in the phase 2 clinical trial for HER-Vaxx, and final OS data expected Q2, 2022.
Any day now indeed ladies and gentleman!
I believe we're going to see fantastic results and 'beautiful data'. Less than 6 days left for the quarter, even if it pushes into next quarter an ANN cannot be far away.
Monoclonal therapy in the form of Trastuzumab occurs every 3 weeks, and takes 3-5hrs per visit, whereas our cancer vaccine Her-vaxx, requires only 2-3 injections and last only a few mintues... and don't forget about the cost savings to patients and their families too!
Image taken from the most recent 'Bioshares Biotech Summit 2022 presentation - May 11, 2022.
Well we've officially crossed the "17.5 month" timeframe alluded...
-
- There are more pages in this discussion • 17,604 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
-0.002(3.77%) |
Mkt cap ! $373.3M | |||
| Open | High | Low | Value | Volume |
| 5.2¢ | 5.2¢ | 5.0¢ | $669.7K | 13.07M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 1074997 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 1209633 | 6 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |